Metastatic Hormone Refractory Prostate Cancer Active Not Recruiting Phase 3 Trials for Abiraterone (DB05812)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03072238Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate CancerTreatment
NCT01957436A Phase III Study for Patients With Metastatic Hormone-naïve Prostate CancerTreatment